Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNK2 | Q07912 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | DHFR | P00374 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | NPY1R | P25929 | 1/20 | 0.35 |
| ▸ | NPY2R | P49146 | 1/20 | 0.35 |
| ▸ | NPY4R | P50391 | 1/20 | 0.35 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | ACACB | O00763 | 4/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.34 |
| ▸ | ACP1 | P24666 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29080221 | 0.91 | ACACB (0.34) | NPY1RNPY2RNPY4RNPY5RACACB | |
| SCHEMBL21400656 | 0.84 | APP (0.44) | MEN1KMT2ANPC1RAB9AACACB | |
| SCHEMBL13226026 | 0.82 | ACP1 (0.33) | TNK2MEN1KMT2AACACBACP1 | |
| SCHEMBL18284504 | 0.82 | MEN1 (0.39) | TNK2MEN1KMT2ADHFRNPC1 | |
| SCHEMBL26842987 | 0.82 | MEN1 (0.36) | TNK2MEN1KMT2ADHFRNPC1 | |
| SCHEMBL1932032 | 0.82 | ACACB (0.47) | TNK2MEN1KMT2ADHFRACACB | |
| SCHEMBL24619846 | 0.81 | DHFR (0.36) | DHFRNPC1RAB9AKDM4C | |
| SCHEMBL21400657 | 0.81 | APP (0.44) | TNK2MEN1KMT2ADHFRNPY1R | |
| SCHEMBL3500438 | 0.81 | TNK2 (0.44) | TNK2MEN1KMT2ADHFRNPC1 | |
| SCHEMBL7234221 | 0.80 | PDE4B (0.38) | DHFRNPC1RAB9AKDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240132431-A1 | METHOD FOR ALKYLATING ACIDIC FUNCTIONAL GROUP | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-04-25 | — | — | US | disclosed |
| EP-4279476-A1 | METHOD FOR ALKYLATING ACIDIC FUNCTIONAL GROUP | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-11-22 | — | — | EP | disclosed |
| EP-4279476-A1 | METHOD FOR ALKYLATING ACIDIC FUNCTIONAL GROUP | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-11-22 | — | — | EP | disclosed |
| WO-2022149618-A1 | METHOD FOR ALKYLATING ACIDIC FUNCTIONAL GROUP | 中外製薬株式会社 | 2022-07-14 | — | — | WO | disclosed |
| WO-2022149618-A1 | METHOD FOR ALKYLATING ACIDIC FUNCTIONAL GROUP | 中外製薬株式会社 | 2022-07-14 | — | — | WO | disclosed |
| CN-104119285-B | Compound and application thereof as estrogen-related receptor modulator | 中国科学院广州生物医药与健康研究院 | 2016-06-29 | — | — | CN | disclosed |
| CN-104119285-A | Compound used as estrogen-related receptor regulator and application of compound | GUANGZHOU INST BIOMED & HEALTH | 2014-10-29 | — | — | CN | disclosed |
| US-8716355-B2 | Hydroxylated tolans and related compounds in the treatment of a cancer | KENT STATE UNIVERSITY (US) | 2014-05-06 | — | — | US | disclosed |
| US-8716355-B2 | Hydroxylated tolans and related compounds in the treatment of a cancer | KENT STATE UNIVERSITY (US) | 2014-05-06 | — | — | US | disclosed |
| US-8716355-B2 | Hydroxylated tolans and related compounds in the treatment of a cancer | KENT STATE UNIVERSITY (US) | 2014-05-06 | — | — | US | disclosed |
| US-20110130468-A1 | HYDROXYLATED TOLANS AND RELATED COMPOUNDS IN THE TREATMENT OF A CANCER | KENT STATE UNIVERSITY (US) | 2011-06-02 | — | — | US | disclosed |
| US-20110130468-A1 | HYDROXYLATED TOLANS AND RELATED COMPOUNDS IN THE TREATMENT OF A CANCER | KENT STATE UNIVERSITY (US) | 2011-06-02 | — | — | US | disclosed |
| WO-2008157745-A1 | ASCORBATE, VITAMIN K3 AND HYDROXYTOLANS IN THE TREATMENT OF CANCER | KENT STATE UNIVERSITY (US) | 2008-12-24 | — | — | WO | disclosed |
| WO-2008157787-A2 | HYDROXYLATED TOLANS AND RELATED COMPOUNDS IN THE TREATMENT OF CANCER | KENT STATE UNIVERSITY (US) | 2008-12-24 | — | — | WO | disclosed |
| US-7094809-B2 | Topical administration of dihydroxytoluene to block viral replication | NORTHEASTERN OHIO UNIVERSITIES COLLEGE OF MEDICINE (US) | 2006-08-22 | — | — | US | disclosed |
| US-20030203974-A1 | Methods for treating subjects infected with herpes virus or Neisseria gonorrheae | DOCHERTY JOHN (US) | 2003-10-30 | — | — | US | disclosed |
| US-6599945-B2 | Administering a hydroxylated tolan to the host cell of a patient having or suspected having an infection induced by herpes virus | NORTHEASTERN OHIO UNIVERSITIES COLLEGE OF MEDICINE | 2003-07-29 | — | — | US | disclosed |
| EP-1311254-A2 | METHODS FOR TREATING SUBJECTS INFECTED WITH A HERPES VIRUS OR i NEISSERIA GONORRHEAE /i | Northeastern Ohio Universities (US) | 2003-05-21 | — | — | EP | disclosed |
| US-20020103262-A1 | Methods for treating subjects infected with a herpes virus or neisseria gonorrheae | KENT STATE UNIVERSITY | 2002-08-01 | — | — | US | disclosed |
| WO-2002013764-A2 | METHODS FOR TREATING SUBJECTS INFECTED WITH A HERPES VIRUS OR NEISSERIA GONORRHEAE | NORTHEASTERN OHIO UNIVERSITIES COLLEGE OF MEDICINE (US) | 2002-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130468-A1 | HYDROXYLATED TOLANS AND RELATED COMPOUNDS IN THE TREATMENT OF A CANCER | TKT, HAAO, TTPA | TNK2 1875/4885MEN1 3316/4885KMT2A 1087/4885 |
| US-20240132431-A1 | METHOD FOR ALKYLATING ACIDIC FUNCTIONAL GROUP | MGMT, MCL1, FANCF | TNK2 1498/4885MEN1 1437/4885KMT2A 721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.